A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...

Formosa Pharmaceuticals has announced the completion and top-line results from CPN-303, a phase 3 clinical study of APP13007 ...

FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.

The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for ...

The Valeda Light Delivery System is for the treatment of patients with dry age-related macular degeneration (AMD).

Omar Salamanca, MD, staff ophthalmologist, Orbis Flying Eye Hospital, discusses Orbis's tailored glaucoma training programs, which focus on hands-on surgical skills, early detection, telemedicine, and ...

Robert T. Chang, MD, from Stanford University discusses how large language models are transforming ophthalmology by enhancing ...

200 mg of caffeine elevated the blood pressure after 2 hours but did not impact the retinal VD.

Rensselaer researchers receive $6.4 million grant from NEI to seek new treatment for blindness-causing diseases.

Dropless cataract surgery eliminates postoperative eye drops, enhancing patient adherence and reducing complications like ...

In this final episode, DMEI’s residents share their future plans for expanding the device capabilities and offer practical ...

In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s ...